

Cynata Therapeutics Receives Notice of Allowance from Canadian Patent Office for Cymerus™ Patent Application

Melbourne, Australia; 25 October 2019: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP or “the Company”), announced today that a Notice of Allowance has been received from the Canadian Intellectual Property Office (CIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum free conditions” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

The Notice of Allowance is sent to the applicant when the CIPO intends to issue a patent. The patent will expand the already strong IP protection of the Cymerus platform and its unique ability to manufacture mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

“We continue to build our already comprehensive patent portfolio to protect our unique and proprietary IP and are committed to strengthening it with further applications,” said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “The ability of the Cymerus platform to enable manufacture of consistent, high-quality mesenchymal stem cells at scale is key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide. The successful completion of our Phase 1 clinical trial in acute steroid resistant graft-versus-host disease, in which all endpoints were met, together with our recent license transaction with Fujifilm, provides clear validation of our technology.”

The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.

Cynata anticipates that the patent will be granted before 11 April 2020, with an expiration date of 16 March 2031.

-ENDS-

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve



economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.

Cynata Therapeutics Limited

Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia
PO Box 7165, Hawthorn North, Victoria 3122

T: + 613 9824 5254 F: + 613 9822 7735 E: info@cynata.com

ABN - 98 104 037 372